

# PMPRB HEARING WITH ALEXION CANADA

## 2009

The PMPRB designates Soliris® (eculizumab) as a breakthrough, innovative product

Alexion prices Soliris in accordance with the PMPRB's guidelines

### PMPRB GUIDELINES

- The price of a "breakthrough" product is measured against the publicly-available prices of the same product in 7 comparator countries
- Price of product cannot rise to become the highest among the comparator countries, under Guidelines' Highest International Price Comparison test

# ↓ 10%

Adjusted for inflation, the price of Soliris has fallen 10% since 2009 in Canada

## 2010-2011

The PMPRB does not find the price of Soliris excessive in 2010 and 2011



## 2015

The PMPRB alleges the price of Soliris in Canada was excessive from 2012 to 2014



The 2009 price never increased. The only thing that changed is the foreign exchange rate between the Canadian dollar and the currencies of the comparator countries, something Alexion does not control



## 2016

PMPRB proposes an entirely new regulatory structure, a departure from the guidelines used to set the price of Soliris

If implemented, will have serious implications for Canada's biotech industry and detract from future innovations and investments

### PMPRB INTRODUCES NEW ALLEGATIONS

- Seek to retroactively apply Lowest International Price Comparison test
- Declares the price of Soliris in Canada as excessive because it is higher than the lowest international price



### ALEXION'S COMMITMENT

- Develop and deliver life-transforming therapies for patients with devastating and rare diseases that have no effective treatment options
- Fund in-home and private clinic infusion costs associated with Soliris
- Provide the drug free for eligible patients while they pursue insurance coverage

### DID YOU KNOW?

- The PMPRB Board employs both Panel and Board Staff prosecuting the case
- The former PMPRB Chairperson is also a member of the Board of Directors of private insurance company, Green Shield Canada, and as such, has a conflict of interest
- PMPRB allegations are motivated by misconceptions of the cost of orphan drugs on the healthcare system. In actuality, orphan drugs are only a very small fraction of the overall healthcare budget